Vaccinex Announces Antibody Collaboration with Schering
News Feb 14, 2006
Vaccinex, Inc. has announced that it has entered into research collaboration with Schering AG to identify disease targets and potentially develop therapeutic antibodies for the treatment of certain cancers.
Vaccinex will receive a technology access fee and research funding and is eligible for milestone payments and royalties.
Following the initial research phase, Vaccinex may receive certain options to co-develop a selected cancer product with Schering AG.
Dr. Maurice Zauderer, President and CEO of Vaccinex commented, "We are very excited about applying our proprietary technologies to validate several of Schering AG's oncology targets as well as to have an opportunity to collaborate in co-developing a promising cancer product."
"We are especially pleased to be working together with an accomplished pharmaceutical partner like Schering on the discovery and development of new and innovative treatments for cancer and other diseases."
Antitumor Immune Function in Liver Controlled by Gut MicrobiomeNews
Scientists have found a connection between bacteria in the gut and antitumor immune responses in the liver. The study showed that bacteria found in the gut of mice affect the liver’s antitumor immune function. The findings have implications for understanding the mechanisms that lead to liver cancer and for therapeutic approaches to treat them.READ MORE
You Are What Your Mother EatsNews
While many factors, such as the age of the mother, overall health and genetics ultimately play a role, the correlation between a mother’s nutrition habits and metabolism has been proved to directly impact the growth of her child. And researchers believe they may be one step closer to knowing why.READ MORE